Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial
NCT ID: NCT01143948
Last Updated: 2010-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
45 participants
INTERVENTIONAL
2011-01-31
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lyspro Insulin vs Regular Insulin in Cirrhotic Patients
NCT00513201
Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes
NCT05641337
Liver Glycogen and Hypoglycemia in Humans
NCT03241706
Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia
NCT06178874
Comparing Efficacy Between Two Protocols of Intravenous Insulin Infusion for Diabetic Adults in ICU
NCT06810596
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
15 patient sliding scale regular insulin
Regular insulin
Sliding scale regular insulin
15 patient BBI NPH plus regular insulin
NPH & regular insulin
Basal NPH \& bolus regular insulin
15 patients BBI Glargine plus Glulisine
Glargine & Glulisine
Basal Glargine \& bolus Glulisine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glargine & Glulisine
Basal Glargine \& bolus Glulisine
Regular insulin
Sliding scale regular insulin
NPH & regular insulin
Basal NPH \& bolus regular insulin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Entry blood glucose (fasting or random) greater than 180 mg%
Exclusion Criteria
* Pregnancy
* Steroids: prednisone greater than 7.5mg/day or equivalent
* Serum Creatinine \> 3 mg/dl
* Patients in intensive care units.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cairo University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ibtisam Z Eissa, MD
Role: STUDY_CHAIR
Cairo University
Mary N Rizk, MD
Role: STUDY_DIRECTOR
Cairo Univerity
Ahmad A Khairy, MD
Role: STUDY_DIRECTOR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Internal medicine hospital ,Cairo University
Cairo, Cairo Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Balkau B, Eschwege E, Ducimetiere P, Richard JL, Warnet JM. The high risk of death by alcohol related diseases in subjects diagnosed as diabetic and impaired glucose tolerant: the Paris Prospective Study after 15 years of follow-up. J Clin Epidemiol. 1991;44(6):465-74. doi: 10.1016/0895-4356(91)90209-r.
de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999 May;22(5):756-61. doi: 10.2337/diacare.22.5.756.
Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007 Mar;30(3):734-43. doi: 10.2337/dc06-1539. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LC-T2D
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.